Equibles does not estimate personal net worth.
Get an email with a short summary when Generate Biomedicines, Inc. publishes a filing, an earnings call transcript or a press release.
Get GENB alertsMichael Nally is recorded as CEO at Generate Biomedicines, Inc. (GENB). Michael Nally has spoken on 3 investor events across 1 company, most recently for Generate Biomedicines, Inc. on November 9, 2026. Generate Biomedicines, Inc. is classified in the Biotechnology industry within the Healthcare sector.
“You know, generate... It's been really fun being at Generate. You know, I've now been at Generate almost six years after having spent 18 years at Merck. And when I joined the company, it was going after a premise that nobody in the world believed in, that generative AI could actually design protein therapeutics.”
“We have three and you know I guess sort of how is the rise of China origin innovation changing your competitive position in R&D versus your business development playbook if at Yeah, so I think China, Sean, has been, I think, nothing short of miraculous in terms of the ability to brute force their way to exceptional…”
“It's great to be here and excited to share a little bit more about Generate and the story. So Generate's a company that was founded in 2018 with a fundamental premise that, you know, a data-driven approach to protein design could lead to superior outcomes.”
Biotechnology · Healthcare
CEO
